Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10O6 |
Molecular Weight | 286.2363 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)C2=C(O)C(=O)C3=C(O)C=C(O)C=C3O2
InChI
InChIKey=IYRMWMYZSQPJKC-UHFFFAOYSA-N
InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H
Molecular Formula | C15H10O6 |
Molecular Weight | 286.2363 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a flavonoid found in many edible plants (e.g. tea, broccoli, cabbage, kale, beans, endive, leek, tomato, strawberries and grapes) and in plants or botanical products commonly used in traditional medicine (e.g. Ginkgo biloba, Tilia spp, Equisetum spp, Moringa oleifera, Sophora japonica and propolis). Numerous preclinical studies have shown that kaempferol and some glycosides of kaempferol have a wide range of pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer, cardioprotective, neuroprotective, antidiabetic, anti-osteoporotic, estrogenic/antiestrogenic, anxiolytic, analgesic and antiallergic activities.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26419945 |
|||
Target ID: CHEMBL2345 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24994661 |
|||
Target ID: CHEMBL4237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24994661 |
|||
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10813558 |
0.7 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.46 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27749255 |
250 mg/kg single, oral dose: 250 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3.84 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27749255 |
25 mg/kg single, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26051640 |
6 mg/kg single, oral dose: 6 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.51 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27749255 |
250 mg/kg single, oral dose: 250 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.17 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27749255 |
25 mg/kg single, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
17.72 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26051640 |
6 mg/kg single, oral dose: 6 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27749255 |
250 mg/kg single, oral dose: 250 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27749255 |
25 mg/kg single, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
5.11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26051640 |
6 mg/kg single, oral dose: 6 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
KAEMPFEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Medicinal and ethnoveterinary remedies of hunters in Trinidad. | 2001 |
|
Electrochemical behaviors of quercetin and kaempferol in neutral buffer solution. | 2001 Aug |
|
Dietary polyunsaturated fatty acid and antioxidant modulation of vascular dysfunction in the spontaneously hypertensive rat. | 2001 Aug |
|
Four new isoflavone triglycosides from Sophora japonica. | 2001 Aug |
|
Medicinal foodstuffs. XXV. Hepatoprotective principle and structures of ionone glucoside, phenethyl glycoside, and flavonol oligoglycosides from young seedpods of garden peas, Pisum sativum L. | 2001 Aug |
|
Effect of processing and storage on the antioxidant ellagic acid derivatives and flavonoids of red raspberry (Rubus idaeus) jams. | 2001 Aug |
|
Cytotoxicity and lipid peroxidation-inhibiting activity of flavonoids. | 2001 Aug |
|
Inhibitory activity for chitin synthase II from Saccharomyces cerevisiae by tannins and related compounds. | 2001 Aug |
|
The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human cyp1a1 expression. | 2001 Aug |
|
Proposed active constituents of Dipladenia martiana. | 2001 Dec |
|
Inhibition of nitric oxide synthase expression by a methanolic extract of Crescentia alata and its derived flavonols. | 2001 Dec 21 |
|
[Identification of seeds of Cuscuta australis and C. chinensis by TLC and HPLC]. | 2001 Feb |
|
Flavonoids and free phenolic acids from Phytolacca americana L. leaves. | 2001 Jan-Feb |
|
Flavonoids as cycline-dependent kinase inhibitors: inhibition of cdc 25 phosphatase activity by flavonoids belonging to the quercetin and kaempferol series. | 2001 Jul |
|
Specific flavonoids induced nod gene expression and pre-activated nod genes of Rhizobium leguminosarum increased pea (Pisum sativum L.) and lentil (Lens culinaris L.) nodulation in controlled growth chamber environments. | 2001 Jul |
|
Flavonol content varies among black currant cultivars. | 2001 Jul |
|
Kaempferol, isorhamnetin and their glycosides in the flowers of Asclepias syriaca L. | 2001 Jul-Aug |
|
Isolation and antioxidant activity of galloyl flavonol glycosides from the seashore plant, Pemphis acidula. | 2001 Jun |
|
Flavonol glycosides from Mentha lavandulacea. | 2001 Jun |
|
Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. | 2001 Jun |
|
Flavonoid accumulation patterns of transparent testa mutants of arabidopsis. | 2001 Jun |
|
Kaempferol triosides from Reseda muricata. | 2001 Jun |
|
The flavonoids of leek, Allium porrum. | 2001 Jun |
|
Flavonoids from Aconitum napellus subsp. neomontanum. | 2001 Jun |
|
Flavonoid compounds in the flowers of Kitaibelia vitifolia Willd. (Malvaceae). | 2001 Mar-Apr |
|
A novel acetylated 3-deoxyanthocyanidin laminaribioside from the fern Blechnum novae-zelandiae. | 2001 Mar-Apr |
|
Flavonoids and urate antioxidant interplay in plasma oxidative stress. | 2001 May |
|
Role of lipophilicity and hydrogen peroxide formation in the cytotoxicity of flavonols. | 2001 May |
|
Kaempferol acetylrhamnosides from the rhizome of Dryopteris crassirhizoma and their inhibitory effects on three different activities of human immunodeficiency virus-1 reverse transcriptase. | 2001 May |
|
Antiprotozoal activity of the constituents of Conyza filaginoides. | 2001 May |
|
Two new glycosides from Astragalus caprinus. | 2001 May |
|
Kaempferol and its glycosides in the seeds hair of Asclepias syriaca L. | 2001 May-Jun |
|
In vitro anti-inflammatory effects of quercetin 3-O-methyl ether and other constituents from Rhamnus species. | 2001 Nov |
|
A stabilized flavonoid glycoside in heat-treated Cassia alata leaves and its structural elucidation. | 2001 Nov |
|
Flavonol glycosides from the flowers of Bellis perennis. | 2001 Nov |
|
Phenolic compounds in seven South American Ilex species. | 2001 Nov |
|
Phytochemical and pharmacological analysis of Bauhinia microstachya (Raddi) Macbr. (Leguminosae). | 2001 Nov-Dec |
|
Antioxidant ability of various flavonoids against DPPH radicals and LDL oxidation. | 2001 Oct |
|
Antioxidative components from the aerial parts of Lactuca scariola L. | 2001 Oct |
|
Antipruritic and antidermatitic effect of extract and compounds of Impatiens balsamina L. in atopic dermatitis model NC mice. | 2001 Sep |
|
Antimicrobial activity of Argentine plants used in the treatment of infectious diseases. Isolation of active compounds from Sebastiania brasiliensis. | 2001 Sep |
|
Flavonoids protect neurons from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. | 2001 Sep 15 |
|
Flavonoids and UV photoprotection in Arabidopsis mutants. | 2001 Sep-Oct |
|
Antioxidative phenolic compounds isolated from almond skins (Prunus amygdalus Batsch). | 2002 Apr 10 |
|
The role of UV-B radiation in aquatic and terrestrial ecosystems--an experimental and functional analysis of the evolution of UV-absorbing compounds. | 2002 Feb |
|
A pharmacophore for human pregnane X receptor ligands. | 2002 Jan |
|
Antioxidant activity of flavonoids from Licania licaniaeflora. | 2002 Mar |
|
Hepatoprotective principles from the flowers of Tilia argentea (linden): structure requirements of tiliroside and mechanisms of action. | 2002 Mar |
|
Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. | 2002 Mar 1 |
|
Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. | 2002 Mar 15 |
Patents
Sample Use Guides
humans: orally as a component of plant (e.g. Elaeagnus Angustifolia or Ginkgo Biloba) extracts.
mice: 100 mg/kg/d, p. o. for 6 weeks.
rats: 20 mg/kg; i.p. daily for a period of 28 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27175782
50 μM of kaempferol specifically inhibited the cell viability by approximately 40% in Miapaca-2 cells, 15% in Panc-1 cells, and 10% in SNU-213 cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 00:51:46 UTC 2023
by
admin
on
Thu Jul 06 00:51:46 UTC 2023
|
Record UNII |
731P2LE49E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
1221 (Number of products:6)
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
KAEMPFEROL
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
DTXSID7020768
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
C68457
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
731P2LE49E
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
28499
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
656277
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
5280863
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
7703
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
208-287-6
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
DB01852
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
407289
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
58573
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
M6592
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | Merck Index | ||
|
520-18-3
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
1354900
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY | |||
|
C006552
Created by
admin on Thu Jul 06 00:51:46 UTC 2023 , Edited by admin on Thu Jul 06 00:51:46 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
The compound was screened for it's antioxidant capacity in the DPPH assay, and displayed a high antioxidant activity, with an IC50 value of 89.7 uM.
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
TRANSPORTER -> INHIBITOR |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |